Extended Survival in Women With Brain Metastases From HER2 Overexpressing Breast Cancer

Abstract

Patients with HER2 overexpressing MBC who received trastuzumab after diagnosis of BM survived longer than expected. This finding justifies an active therapeutic approach: disease progression within central nervous system does not preclude benefit from trastuzumab treatment.